Habte Yimer, MD, discusses findings from follow-up data of the phase 3 ALPINE study that were presented at the 2023 ASH Annual Meeting.
Follow-up data from the phase 3 ALPINE trial (NCT03734016) presented at the 2023 American Society for Hematology (ASH) Annual Meeting showed that zanubrutinib (Brukinsa) demonstrated superior progression-free survival and safety signals compared with ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Here, Habte Yimer, MD, hematologist/oncologist with Texas Oncology and investigator of the study, discusses the findings and implications of the study.
Transcription:
0:09 | Some trials, they show early benefit which might not carry over into 3 years or 5 years marks. Actual progression-free survival benefit that was seen 2 years mark actually persisted to 3 years mark, showing that zanubrutinib still has a better progression-free survival than ibrutinib.
0:33 | We also presented the safety, whether they [are] still carrying over. And even though, for example, if we look at the hypertension, right—hypertension rate is equal between both ibrutinib and zanubrutinib arm. The degree of rise in systolic blood pressure is less with zanubrutininb. And over time, cardiac safety issues also. You see less atrial fibrillation, much less atrial fibrillation and flutter with zanubrutinib. And there were 6 deaths, cardiac related deaths on ibrutinib compare to 0 on zanubrutinib.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More